Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $7.43 Billion |
|---|---|
| Enterprise Value | $8.78 Billion |
| Earnings per Share | $- |
| Beta | 1.49 |
| Outstanding Shares | - |
| P/E Ratio | -2.84 |
|---|---|
| PEG | -30.82 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 11.6 |
| Enterprise Value to EBIT | -4.27 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.22 |
| Debt to Equity | -2.13 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly ...